Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.67 |
| ▸ | GSR | P00390 | 2/20 | 0.60 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.59 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ARG1 | P05089 | 3/20 | 0.54 |
| ▸ | ARG2 | P78540 | 3/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norleucine SCHEMBL8393 | 1.00 | — | — | |
| Norleucine SCHEMBL8392 | 1.00 | — | — | |
| Norleucine SCHEMBL26474 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL198127 | 1.00 | — | — | |
| Norleucine SCHEMBL2785913 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL5497693 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL4608461 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL13736626 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL4163267 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 | |
| Norleucine SCHEMBL15051960 | 0.98 | SLC1A2 (0.64) | SLC1A2SLC1A1SLC1A3GSRDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364695-B | Antibodies specifically recognizing C5A and uses thereof | 舒泰神（北京）生物制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-114072145-B | Antibodies specifically recognizing pseudomonas PCRV and uses thereof | 北京三诺佳邑生物技术有限责任公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118103397-A | Antibodies specifically recognizing TNFR2 and uses thereof | 舒泰神(加州)生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-115023438-B | Antibody combinations specifically recognizing pseudomonas PCRV or PSL antigens and bispecific antibodies | 北京三诺佳邑生物技术有限责任公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117917436-A | Antibody capable of specifically recognizing TRAIL and application thereof | 北京三诺佳邑生物技术有限责任公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117917437-A | Antibody capable of specifically recognizing TRAIL and application thereof | 北京三诺佳邑生物技术有限责任公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-114805487-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113045625-B | Polypeptides as somatostatin receptor agonists and uses thereof | 成都诺和晟泰生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-113072617-B | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023138521-A1 | ANTIBODY SPECIFICALLY RECOGNIZING FASL AND APPLICATION THEREOF | 北京三诺佳邑生物技术有限责任公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2005108561-A2 | RECOMBINANT ENZYME WITH ALTERED FEEDBACK SENSITIVITY | METABOLIC EXPLORER (FR) | 2005-11-17 | — | — | WO | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5739101-A | ADMINISTERING AN ANTICOAGULANTS | GENENTECH, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5698418-A | BOVIN SOMATOTROPIN HETEROLOGOUS POLYPEPTIDE EXPRESSED BY A MUTANT MICROORGANISM GROWN ON A CULTURE MEDIUM HAVING LOW AMINO ACID CONCENTRATION, COMPRISING UTILIZING MUTANT MICROORGANISM TO OVERPRODUCE METHIONINE | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-16 | — | — | US | disclosed |
| US-5622845-A | USING ESCHERICHIA | THE UPJOHN COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5589363-A | DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders | GENENTECH, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0402418-A1 | PHYSIOLOGICAL ACTIVE LIQUID ALLERGENIC COMPOSITION FROM BIOLOGICAL RAW MATERIALS | Tetra Consultants Inc. (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0401254-A1 | METHODS FOR CONTROLLING NORLEUCINE CONTENT IN POLYPEPTIDES. | UPJOHN CO (US) | 1990-12-12 | — | — | EP | disclosed |
| WO-1989010138-A1 | PHYSIOLOGICAL ACTIVE LIQUID ALLERGENIC COMPOSITION FROM BIOLOGICAL RAW MATERIALS | TETRA CONSULTANTS, INC. (US) | 1989-11-02 | — | — | WO | disclosed |
| WO-1989007651-A2 | METHODS FOR CONTROLLING NORLEUCINE CONTENT IN POLYPEPTIDES | THE UPJOHN COMPANY (US) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | SLC1A2 544/4885SLC1A1 937/4885SLC1A3 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.